Evaluation of cannabidiol and urea 10%.
This study evaluated the impact of cannabidiol on neuropathic pain and the action of urea 10% on skin quality in patients with diabetic foot syndrome and diabetic neuropathy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
23
After fulfilling the criteria and agreeing to participate in the study, patients who were included in group 1 after randomisation were evaluated and received a topical cream with cannabidiol, Urea 10%, arnica and menthol as active ingredients. After one month of application of the formula, a second evaluation was carried out.
After meeting the criteria and agreeing to participate in the study, the patients who were included in group 2 after randomisation were evaluated and received a topical cream containing cannabidiol and 10% urea. After one month of application of the formula, a second evaluation was carried out.
Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid
Madrid, Spain
Assessment of neuropathic pain.
Neuropathic pain was assessed using the validated neuropathic pain assessment scale.
Time frame: From randomisation and delivery of the assigned formula until the end of the intervention after one month of application.
Skin quality assessment
The assessment of skin quality was carried out using the validated questionnaire 'Injury Risk and Skin Quality Assessment Questionnaire'.
Time frame: From randomisation and delivery of the assigned formula until the end of the intervention after one month of application.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Participants included in this group after randomisation received a formulation with no active ingredients included in its composition and were assessed at baseline and after one month.